Kenvue

Name

Kenvue

Legal name

Kenvue Inc.

Website

https://kenvue.com

Company type

Public

Founded year

2022

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Consumer Health Products

NAICS

Other Health and Personal Care Retailers (45619)

SIC

Pharmaceutical Preparations (2834), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• Consumer health products
• Over-the-counter medicines
• Skincare and beauty
• Oral care products
• Personal care brands

Headquarters

HQ city

Skillman

HQ country

United States

HQ region

North America

Offices15 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Marketing or Sales, Operations, Personnel, Technology or R&D, Infrastructure

Revenue model

1. Self Care (OTC Medicines): Over-the-counter medicines including Tylenol, Motrin, Benadryl, Zyrtec, and Nicorette generating revenue through retail pharmacy and consumer purchases. Segment reported 1.9% growth in Q1 2026.
2. Skin Health and Beauty: Skincare and beauty products including Neutrogena, Aveeno, OGX, and Rogaine. Segment led performance with 8.4% net sales growth in Q1 2026, supported by innovations including Neutrogena Sun Care expansion.
3. Essential Health: Essential health products including Listerine, Band-Aid, Johnson's Baby, and Imodium. Segment grew 4.9% in Q1 2026.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

Kenvue is the world's largest pure-play consumer health company, manufacturing and marketing a portfolio of iconic over-the-counter medicines, skincare, oral care, baby care, and personal health brands. The company operates across three segments — Self Care (Tylenol, Motrin, Benadryl, Zyrtec, Nicorette, Imodium), Skin Health and Beauty (Neutrogena, Aveeno, OGX, Rogaine), and Essential Health (Listerine, Band-Aid, Johnson's Baby) — distributing products to approximately 1.2 billion consumers across more than 165 countries through retail pharmacies, drugstores, and e-commerce channels.

Product overview

Kenvue is the world's largest pure-play consumer health company, operating as a multi-brand portfolio organized across three segments: Self Care (over-the-counter medicines like Tylenol, Benadryl, Zyrtec, Sudafed, Nicorette, and Imodium), Skin Health and Beauty (Neutrogena, Aveeno, OGX, Rogaine, Clean & Clear, and Zarbees), and Essential Health (Band-Aid, Johnson's Baby, and Calpol). The company markets Listerine for oral care and Benylin for cold symptoms. Brands are distributed globally across retail and e-commerce channels, backed by clinical research and healthcare professional endorsements. Founded in 2022 and spun off from Johnson & Johnson in 2023, Kenvue touches the lives of approximately 1.2 billion consumers across over 165 countries.

Differentiator

Problem solved

Functional benefit

Brands

• Listerine: Oral care mouthwash brand; alcohol-based antiseptic product for reducing plaque and freshening breath.
• Neutrogena
• Aveeno
• Band-Aid
• Tylenol
• Johnson's Baby
• Zyrtec
• OGX
• Rogaine
• Nicorette
• Benadryl
• Le Petit Marseillais
• Imodium
• Sudafed
• Benylin
• Calpol
• Nicorette
• Zarbees
• Clean & Clear

Products and services

• Tylenol

Quantifiable outcome

• 8.4% net sales growth in Skin Health and Beauty segment Q1 2026
• +4 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability9 records

Feature6 records

Partnerships

Ten partnerships are on record, tiered minor and core.

• Fuel TransportminorStrategic or Co-development Partner · 2 June 2026Pilot program called Electric Loop (eLoop) testing electric freight delivery across select urban routes in Greater Toronto Area. Electric truck deployment on short-haul routes evaluating real-world operational performance, energy efficiency, and emissions impact in dense city conditions.
• Asia Pacific Dental FederationminorStrategic or Co-development Partner · 25 May 2026Kenvue (makers of LISTERINE) supported landmark white paper on evidence-based daily oral self-care guidelines. Report highlights brushing reaches only 25% of mouth surfaces; therapeutic mouthwash reduces plaque by 25-50% and gum bleeding by up to 67.8%.
• GreyparrotcoreTechnology or Integration · 20 May 2026Strategic collaboration leveraging Greyparrot's Deepnest AI platform to analyze and validate packaging performance in real-world recycling facilities in UK and US. Moves beyond theoretical design-for-recycling to actual recovery data, enabling packaging circularity improvements and EPR cost forecasting.
• MicrosoftcoreTechnology or Integration · 7 May 2026Multi-year collaboration to modernize digital and data capabilities, aligning dermatologist education, AI-driven insights, and e-commerce execution to support Kenvue's innovation strategy.
• Population Services International IndiaminorStrategic or Co-development Partner · 5 May 2026Collaboration on World Hand Hygiene Day and 'No Fear of Diarrhoea' initiative in Kanpur district, India. Health Department partnership distributing ORS packets and demonstrating proper handwashing techniques.
• CVS Media Exchange (CMX)coreGTM or Marketing Partner · 1 May 2026Retail media partnership where Kenvue leverages CVS's CorIQ AI platform for media planning, real-time optimization, and measurement. Kenvue achieved 30% or greater lift in buyer conversion and basket size through the partnership.
• Essex Bio-Technology LimitedminorStrategic or Co-development Partner · 23 March 2026Collaboration with Kenvue for consumer health products, announced alongside Essex's strategic partnerships for distribution including Beifushu entering Singapore market and MOU with Suzhou Industrial Park for life sciences accelerator.
• Mayo CliniccoreStrategic or Co-development Partner · 10 March 2026Three-year research collaboration with Aveeno brand focusing on skin health science including preclinical and clinical investigations on skin longevity and regeneration. Builds on 80-year history of collaboration dating to 1945 when Musher brothers worked with Mayo Clinic to develop colloidal oatmeal treatments.
• Kimberly-Clark CorporationcoreStrategic or Co-development Partner · 1 November 2025Kimberly-Clark announced plans to acquire Kenvue for approximately $48.7 billion enterprise value, creating a combined entity with ~$32 billion in revenue and $7 billion EBITDA pre-synergies. Deal approved by shareholders in January 2026 with CCI approval in India; expected to close H2 2026. Kenvue shareholders to receive $3.50 per share plus 0.14625 Kimberly-Clark shares per share.
• Sonoma PharmaceuticalsminorOEM/ Whitelabel/ Licensing Partner · 1 October 2025Manufacturing and Supply Agreement for Microcyn technology-based products in US, effective October 2025 through March 2027 with potential extensions. Sonoma also launching new dermatology products and burn relief hydrogel in US retail stores.

Scale indicators16 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Church & Dwight: Church & Dwight (NYSE: CHD) operates in personal care, household, and specialty consumer health with brands including Orajel (oral pain relief competing with Anbesol/Tylenol Oral), Batiste (dry shampoo), and Trojan. The diversified consumer health orientation and North American retail distribution model align closely with Kenvue's approach.
• Reckitt Benckiser: Reckitt (LSE: RKT) operates a Health segment (Mucinex, Delsym, Nurofen, Gaviscon) that directly competes with Kenvue's OTC franchise, plus Hygiene (Lysol, Dettol) and Home care. Reckitt is one of the closest pure-play comparables to Kenvue's OTC + hygiene orientation with similar pharmacy channel distribution.
• L'Oréal: L'Oréal (EPA: OR) is the world's largest beauty company with dermatological brands (CeraVe, La Roche-Posay, Vichy) directly competing with Kenvue's Neutrogena and Aveeno franchises. The Skin Health and Beauty segment faces its most formidable competitor in L'Oréal's Active Cosmetics division, which has captured significant clinical skincare share.
• Estée Lauder: Estée Lauder (NYSE: EL) operates premium skincare and beauty brands (Estée Lauder, Clinique, La Mer) competing with Kenvue's Neutrogena in mass-to-prestige skincare. While more premium-focused, Estée Lauder's dermatological skincare investments and global beauty distribution create direct competitive pressure on Kenvue's Skin Health and Beauty growth.
• Haleon: Haleon (NYSE: HLN) is the world's other major pure-play consumer health company, spun off from GSK in 2022. It directly competes with Kenvue across OTC (Advil vs Tylenol, Centrum vs Flintstones), oral health (Sensodyne vs Listerine adjacent categories), and respiratory health (Panadol, Voltaren). Both companies share the same pure-play consumer health DNA, pharmacy distribution model, and brand-driven growth strategy.
• Beiersdorf: Beiersdorf (XETRA: BEI) is a global skincare leader with Nivea, Eucerin, La Prairie, and Hansaplast directly competing with Kenvue's Neutrogena, Aveeno, and Band-Aid franchises. The dermatological positioning, OTC adjacency (Eucerin), and global skincare scale make Beiersdorf a direct peer in Skin Health and Beauty and wound care.
• Bayer Consumer Health: Bayer's Consumer Health division (part of XETRA: BAYN) includes Aspirin, Claritin, Aleve, and Coppertone (now sold to Kenvue-aligned brands), directly competing with Kenvue's pain relief, allergy, and sun care franchises. The portfolio overlap in OTC analgesics and sun protection makes Bayer Consumer Health a direct comparable.
• Colgate-Palmolive: Colgate-Palmolive (NYSE: CL) is the global oral care leader (Colgate, Tom's of Maine, meridol) directly competing with Kenvue's Listerine franchise, plus personal care (Palmolive, Softsoap) overlapping with Kenvue's body care brands. The business model alignment and shared retail channels make Colgate one of Kenvue's most direct competitors.

Broad incumbents

• Procter & Gamble: P&G (NYSE: PG) is a diversified CPG incumbent with overlapping brands including Vicks (OTC cold), Pepto-Bismol (digestive), Align (probiotics), Oral-B (oral care), and Gillette (personal care). While P&G is much broader than Kenvue, the consumer health portfolio competes directly across most of Kenvue's Self Care and Essential Health segments.
• Johnson & Johnson: Johnson & Johnson (NYSE: JNJ) was Kenvue's parent company until the May 2023 spin-off and continues to operate in adjacent consumer health-adjacent categories through its pharma and medtech segments. While J&J divested its consumer health business, the historical parent relationship, overlapping R&D heritage, and ongoing competitive dynamics make J&J a relevant broad incumbent comparable.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Kenvue
• LinkedInlinkedin.com/company/kenvue
• Instagraminstagram.com/kenvue
• Xx.com/kenvue

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries12 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kenvue